Nurix Therapeutics Profit Margin

Nurix Therapeutics (NRIX) currently reports a profit margin of 42.01% as of August 2026. That compares with -292.5% in the prior-year period — up 114.4% year over year. That is above the Healthcare sector average of 19.13%. Use the charts on this page to explore Nurix Therapeutics's profit margin history and peer comparisons.

Nurix Therapeutics's profit margin increased from -292.5% to 42.01% — a 114.4% year-over-year increase (period ending August 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nurix Therapeutics's profit margin of 42.01% is higher than the Healthcare sector average of 19.13%. That is roughly 119.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Nurix Therapeutics's current 42.01% should be judged against Healthcare norms (sector average: 19.13%) and against NRIX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 42.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Nurix Therapeutics, and consider following NRIX for alerts when major investors trade the stock.